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Accepted 1 September 2016Dietary supplements (DSs) can be obtained over-the-counter but can also be prescribed by
health-care providers for therapeutic reasons. Few studies have documented this later source
despite the fact that 79% of physicians and 82% of nurses have recommended DSs to patients.
This investigation assessed prevalence and temporal trends in oral DS prescriptions filled by
all United States service members (SMs) from 2005 to 2013 (n = 1 427 080 ± 22 139, mean ±
standard deviation (SD)/y). We hypothesize that there would be temporal variations in
specific types of DSs. Data obtained from Department of Defense Pharmacy Data
Transaction System were grouped by American Hospital Formulary System
pharmacologic-therapeutic classifications and prevalence examined over time. About
11% of SMs filled one or more DS prescriptions of 235 180 ± 4926 (mean ± SD)
prescriptions/y over the 9-year period. Curve-fitting techniques indicated significant
linear declines over time for multivitamins (P = .004), iron preparations (P < .001), antacids
(P < .001), and vitamin B and B complex vitamins (P < .001). There were significant
quadratic trends indicating a rise in early years followed by a leveling off in later years for
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1141N U T R I T I O N R E S E A R C H 3 6 ( 2 0 1 6 ) 1 1 4 0 – 1 1 5 2quadratic trends (P < .001) for vitamin E indicating a decline in early years and leveling off
in later years, and vitamin D indicating little change in early years followed by a large rise
subsequently (P < .001). This study identified temporal trends in specific DS categories
that may be associated with changing perceptions of prescribers and/or patients of the
appropriate roles of DSs in medicine and public health.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dietary supplements (DSs) are commercially available prod-
ucts that are consumed as an addition to the usual diet. DSs
include vitamins, minerals, herbs (botanicals), amino acids,
and a variety of other substances [1]. Recent surveys of health
care providers found that 79% of physicians, 82% of nurses,
and 97% of dietitians had recommended DSs to their patients
[2,3]. It is estimated that about 50% of Americans and 60% to
70% of US military personnel use DSs.[4-6]. The Dietary
Supplement Health and Education Act (DSHEA) of 1994 [7]
established the regulatory framework for DSs in the US. Since
DSHEA became law, US sales of DSs has increased from $4
billion in 1994 to $37 billion in 2014, [8,9] a >9-fold increase
over 20 years.
Individuals can obtain DSs from over-the-counter sources
like drug stores, grocery stores, and retailers that specialize in
these substances. In addition to these sources, DSs can be
obtained from prescriptions written by medical care pro-
viders. The types of DSs that are medically prescribed and
their prevalence of use likely differ from those obtained over-
the-counter. The primary reason individuals report for using
over-the-counter DSs is to promote general health [10-12]. DSs
prescribed bymedical personnel are for particular therapeutic
purposes, for example to correct vitamin, mineral, or nutritive
(e.g., amino acid) deficiencies [13]. DSs can also be recom-
mended by health care providers as alternatives to other
types of medications. Pharmaceutical grade DSs do not
appear to carry the same potential risk for contamination or
adverse effects as do some over-the-counter products [14-16].
A number of investigations have quantified the prevalence
of over-the-counter DS use among civilians [5,6,17,18] and
military personnel [4,10,16]. However, investigations on
medically prescribed DSs are more limited. A few studies
have examined population-level prescribed DS use among
civilians, but these studies are based on self-reports rather
than information obtained from medical records [19-21].
Other studies have examined some limited prescription data
within the US military medical system [22-24].
In the US military health care system, medical care is
freely available to service members (SMs) and since there
are no charges for prescription medications, SMs are likely to
fill prescriptions within the system. Information on prescrip-
tions dispensed to SMs is documented by the US Department
of Defense Pharmacy Data Transaction System (PDTS),
thereby providing an opportunity to examine prevalence and
temporal trends in prescriptions filled by all US SMs. These
temporal trends may reflect patterns present in the general
medical community for which such comprehensive data are
not available. We hypothesized that although the overall
prevalence of prescriptions would remain relatively stableover time, there would be temporal variations in specific
categories of DSs. We tested this by obtained DS data from the
PDTS, grouping these data by American Hospital Formulary
System (AHFS) pharmacologic-therapeutic classifications,
and examining changes over time in DS prescriptions.2. Methods and materials
This was a descriptive study designed to identify patterns of
oral DSs filled by the entire population of US military SMs
from 2005 through 2013. SMs included only active duty
personnel in the Army, Navy, Marine Corps, Air Force, and
Coast Guard. DSs were defined based on the Dietary Supple-
ment Health and Education Act of 1994 as “…a product (other
than tobacco) intended to supplement the diet that bears or
contains one or more of the following dietary ingredients: (a) a
vitamin; (b) a mineral; (c) a herb or other botanical; (d) an
amino acid; (e) a dietary substance for use by man to
supplement the diet by increasing total dietary intake; or (f)
a concentrate, metabolite, constituent, extract or combination
of any ingredient in clause a to e” [1]. The study was approved
by the institutional review board of the US Army Research
Institute of Environmental Medicine in accordance with Army
Regulation 70-25 (Use of Volunteers as Subjects of Research).
2.1. Identification of dietary supplements
To identify DSs available for prescription to SMs, 2 databases
were queried. One database was the Food and Drug Admin-
istration National Drug Code (NDC) database, obtained in
November 2013 [25]. At the time, the NDC database contained
65 536 listed substances. The other database was the basic
and extended core formularies of the US Defense Health
Agency's Pharmacoeconomic Center (PEC) [26]. Using the
search engine at the PEC website [26], the following search
terms were used to identify substances classified by First Data
Bank as Generic Class 3 (GC3) categories of drugs which could
also be DSs: vitamins, minerals, protein and amino acids,
herbs and botanical ingredients, fish oil, creatine, joint
support, digestive, and dietary supplements. The GC3 system
utilizes 3 characters (alpha, numeric, and alpha) to represent
the organ system, pharmacological class, and specific thera-
peutic class. A total of 34 901 listed substances were identified
and the corresponding NDC numbers, GC3 numbers, and
generic names were provided by a pharmacist from the
Defense Health Agency Pharmacy Operations Division. A
nutritionist and a physiologist/epidemiologist knowledgeable
in DSs each independently examined the two databases to
identify DSs. After the independent evaluations, the 2
individuals met to resolve any discrepancies. Only substances
Table 1 – Service members by years 2005 through 2013 a
Year Total population (n) Men (%) Women (%)
2005 1 415 217 85.5 14.5
2006 1 405 170 85.6 14.4
2007 1 399 799 85.9 14.2
2008 1 419 049 85.7 14.2
2009 1 444 132 85.7 14.3
2010 1 458 363 85.5 14.5
2011 1 456 505 85.4 14.6
2012 1 435 364 85.2 14.8
2013 1 410 123 85.2 14.8
a Service members represents the entire population of service
members (Army, Navy, Air Force, Marine Corps, and Coast Guard)
for the years specified. Data are obtained from the Armed Forces
Health Surveillance Branch of the Defense Health Agency.
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listed as “unapproved homeopathics” were excluded. After
eliminating overlapping substances in the two databases, the
process resulted in the identification of 25 291 unique oral DS
substances with distinctive NDCs and GC3s (A1B, B3K, C1B,
C1D, C1F, C1H, C1P, C1W, C3B, C3C, C3M, C5B, C5F, C5G, C5H,
C5U, C6A, C6B, C6C, C6D, C6E, C6F, C6G, C6H, C6I, C6L, C6M,
C6N, C6P, C6Q, C6R, C6T, C6Z, C8E, D4B, D4N, D6S, E0A, E0G,
M4B, M4O, P4D, U5B, U6 W, and Z1E) codes.
2.2. Extraction of pharmacy records
Once the DSs were identified, data were extracted from PDTS
records. PDTS is a central data system for all prescription data
from all Department of Defense pharmacy services and
civilian pharmacies that fill prescriptions for SMs. It contains
the name and NDCs of prescriptions dispensed to SMs. NDCs
were used as the unit of identification to obtain DSs
dispensed to SMs. The PDTS database was queried to obtain
both the number of SMs filling one or more DS prescriptions
and the number of prescriptions for each year from 2005
through 2013. Because of the large number of NDCs, the list
was further reduced by grouping the NDC codes according to
their generic names, as listed in the database (eg, aluminum
hydroxide, cholecalciferol, arginine, calcium, psyllium). In 53
cases, there were no generic names listed but 48 of these
records were some form of Vitamin E and so these were given
this generic name. The other 5 substances were not pre-
scribed in the period examined. Using generic names resulted
in 1711 categories. Of the 1711 generic categories, 488 had at
least one SM receiving a prescription in the survey period.
A pharmacist placed the generic substances into the AHFS
Pharmacologic-Therapeutic classifications [13]. After this, sev-
eral AHFS Pharmacologic-Therapeutic classifications were
combined because they were subcategories of higher tier
AHFS codes, had a small number of prescriptions in the
particular therapeutic classes, and/or had very similar thera-
peutic classifications. One group of pharmacologic-therapeutic
classifications that were combined were 28:20.00 (Anoxergenic
Agents and Respiratory and Cerebral Simulants), 28:20.32
(Respiratory and Central Nervous System Stimulants), and
28:20.92 (Anoxergenic Agents and Stimulants, Miscellaneous).
The other pharmacologic-therapeutic classifications that were
combined were 92:00.00 (Miscellaneous Therapeutic Agents)
and 92:92.00 (Other Miscellaneous Therapeutic Agents). This
resulted in 14 AHFS classification groups.
2.3. Statistical analyses
Two measures were calculated for each year for each AHFS
pharmacologic-therapeutic classification. The first calcula-
tion involved the number of SMs filling DS prescriptions and
the second calculation involved the number of DS prescrip-
tions dispensed. The first calculation was called the “SM
prevalence” and was calculated as (∑ of SMs filling one or
more prescription in a particular year and AHFS classification
divided by ∑ of SMs for the year) × 1000 (SMs with one or
more prescriptions/1000 SMs). The second calculation was
called the “prescription prevalence” and was calculated as
(∑ prescriptions in a particular year and AHFS classificationdivided by the ∑ SMs for the year) × 1000 (prescriptions/1000
SMs). The second number was greater than the first because
SMs could fill more than one prescription in a therapeutic
classification for a particular year. The Armed Forces Health
Surveillance Branch (AFHSB) of the Defense Health Agency
provided denominators (∑ SMs for each year) that allowed
calculation of SM and prescription prevalence.
Data were graphed by year to examine trends in prescrip-
tions by AHFS codes [13] during the survey period. Descriptive
statistics were not necessary since the data included all SMs
and the point values on the graphs represent the population
values. To more adequately describe the trends, curve-fitting
techniques were applied to the graphed data, primarily using
linear and quadratic models [27]. The trend line for the
technique that best fit the data (ie, highest r2) was displayed
on the graphs along with the equation. With 7 degrees of
freedom (number of survey years minus two), an r ≥ 0.67 was
significant at the P ≤ .05 level and r ≥ 0.80 was significant at the
P ≤ .01. In the case where a simple linear regression fit the
data, it was possible to estimate the change in prevalence
over the survey period. This was not possible with polynomial
fitting techniques because the change varied over time (ie,
was not linear).3. Results
Table 1 presents the total number of SMs in the years 2005
through 2013. The highest service member census was in
2010, the lowest in 2007, and themean ± SD was 1 427 080 ± 22
139 SMs. During the 9-year surveillance period, 2 116 617
prescriptions for oral DSs were filled for SMs, a mean ± SD of
235 180 ± 4926 per year. A number of SMs filled multiple
prescriptions: 1 448 752 SMs filled one or more prescriptions
for oral DSs during the period a mean ± SD of 160 972 ± 5128
per year. The yearly mean ± SD for SMs was 1 427 080 ± 22 139
so that 11.3% (160 972/1 427 080) of SMs filled a prescription for
an oral DS during the survey period.
Table 2 presents the yearly number of SMs filling oral DS
prescriptions and the number of prescriptions filled, both
classified by AHFS codes. There were very few prescriptions
for the AHFS pharmacologic-therapeutic categories (1)
Table 2 – Oral dietary supplements dispensed to active duty service members by year and categorized by AHFS
pharmacologic-therapeutic classifications
AHFS
Code
AHFS
description
Generic
categories
(n)
Service members filling oral DS prescriptions (n)
2005 2006 2007 2008 2009 2010 2011 2012 2013 2005–2013
20:04.04 Iron
preparations
58 17 876 17 502 17 538 17 269 17 488 17 288 17 350 16 909 16 254 155 474
28:20.00,
28:20.32,
28:20.92
Anoxergenics;
respiratory,
CNS stimulants
3 3 5 3 1 3 3 2 5 4 32
40:12.00 Replacement
preparations
48 21 402 22 345 26 026 29 101 28 706 31 642 32 278 29 254 25 373 246 127
40:20.00 Caloric agents 8 16 17 47 25 68 48 18 18 54 311
56:04.00 Antacids and
absorbents
14 11 690 12 022 8923 7300 7740 6307 6382 5562 4963 70 889
56:12.00 Cathartics
and laxatives
19 22 795 23 631 23 397 23 317 17 768 17 431 19 412 21 465 21 447 190 663
56:92.00 GI Drugs,
miscellaneous
1 1 2 3 2 1 2 1 1 0 13
88:04.00 Vitamin A 4 37 26 11 25 20 14 9 12 23 177
88:08.00 Vitamin B
and B-complex
48 20 818 20 540 18 876 16 846 15 666 14 329 13 780 13 715 12 379 146 949
88:12.00 Vitamin C 3 6739 8750 10 857 12 089 12 324 11 709 11 678 12 503 11 512 98 161
88:16.00 Vitamin D 5 469 718 1112 2097 4643 11 043 15 154 18 903 25 786 79 925
88:20.00 Vitamin E 4 1409 912 793 702 410 361 322 381 392 5682
88:28.00 Multivitamin
preparations
222 51 253 49 453 49 988 50 997 51 691 51 039 50 229 49 123 48 423 452 196
92:00.00,
92:92.00
Therapeutic
agents;
miscellaneous
therapeutic
agents
51 218 160 196 232 411 230 216 250 243 2156
AHFS
Code
AHFS
Description
Generic
Categories
(n)
Total Prescriptions for Oral DSs (n)
2005 2006 2007 2008 2009 2010 2011 2012 2013 2005–2013
20;04.04 Iron
preparations
58 24 833 24 187 24 212 22 928 23 478 23 638 23 483 23370 22547 212 676
28:20.00,
28:20.32,
28:20.92
Anoxergenics;
respiratory,
CNS stimulants
3 3 4 3 0 3 3 2 6 4 28
40:12.00 Replacement
preparations
48 30 513 31 637 35 133 38 170 37 608 41 100 42 079 38737 34502 329 478
40:20.00 Caloric agents 8 16 18 52 27 68 49 19 20 58 327
56:04.00 Antacids and
absorbents
14 14 871 15 044 11 479 9415 9979 7905 8240 7203 5984 90 120
56:12.00 Cathartics
and laxatives
19 27 092 28 141 27 729 27 335 21 417 21 167 23 656 26261 26076 228 874
56:92.00 GI Drugs,
miscellaneous
1 1 3 3 2 1 2 1 1 0 14
88:04.00 Vitamin A 4 44 31 15 30 23 17 12 16 33 221
88:08.00 Vitamin B
and B-complex
48 50 195 53 372 49 333 41 489 36 062 33 092 31 046 30177 24678 349 444
88:12.00 Vitamin C 3 8110 10 098 12503 13 644 14 334 13 358 13 811 14855 13751 114 464
88:16.00 Vitamin D 5 885 1167 1786 3256 7195 16 158 22 116 27284 36875 116 722
88:20.00 Vitamin E 4 2043 1380 1128 1084 576 478 455 616 594 8354
88:28.00 Multivitamin
preparations
222 77 168 74 636 74 599 72 329 74 845 74 580 72 651 72086 69898 662 792
92:00.00,
92:92.00
Therapeutic
agents;
miscellaneous
therapeutic
agents
51 269 211 258 340 513 349 364 412 384 3100
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ulants, (2) caloric agents, (3) gastrointestinal drugs, (4)
Vitamin A, and (5) therapeutic agents. These 5 categories
accounted for <0.2% of all individuals filling prescriptions and
werenot considered further.Multivitaminpreparationswere the
AHFS category accounting for the largest number of individuals
filling prescriptions, followed by replacement preparations,
cathartics and laxatives, iron preparations and B and B-
complex vitamins. Multivitamin preparations were also the
AHFS category accounting for the largest number of prescrip-
tions filled while B and B-complex vitamins had the second
highest number of prescriptions, followed by replacement
preparations, cathartics and laxatives, and iron preparations.
3.1. Overall prevalence and trends and multivitamin
prevalence and trends
Fig. 1A shows the trend in all oral DS prescriptions. There
were only small yearly increases in the prevalence of SMs
filling prescriptions (0.93 prescriptions/1000 SMs/y) and little
systematic change in prescription prevalence. SM preva-
lence varied between 109.3 and 118.3 SMs/1000 SMs, while
prescription prevalence varied between 163.4 and 170.8
prescriptions/1000 SMs. For multivitamin preparations (Fig.
1B), there was a very slight decline over time in the
prevalence of SMs filling prescriptions and the prevalence
of prescriptions filled. Linear regression (slope of the regres-
sion equation) indicated the decline in the SM prevalence for
multivitamins was 0.23 SMs/1000 SMs/y, and the decline in
prescription prevalence was 0.59 prescriptions/1000 SMs/y.
SM prevalence varied from 34.2 to 36.2 SMs/1000 SMs, while
prescription prevalence varied from 49.5 to 54.5 prescrip-
tions/1000 SMs.y = 0.925x + 108.18
R² = 0.583, SEE=2.288, P = .017
y = 0.4924x2 - 5.3409x + 175.97
R² = 0.440, SEE=4.246, P = .053
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Fig. 1 – Service member prevalence andprescriptionprevalence for a
Data were graphed by year to examine trends in prescriptions by AH
applied to the graphed data, primarily using linear and quadratic mo3.2. Iron preparations
For iron preparations (Fig. 2A), there was a very small decline
in the prevalence of SMs receiving these, amounting to 0.19
SMs/1000 SMs/y. or 1.71 SMs/1000 over the 9-year period. This
slight decline was also seen in the prevalence of prescriptions
amounting to 0.13 SMs/,1000 SMs per year or 1.17 SMs/1000/y
over the 9-year period. SM prevalence varied from 11.5 to 12.6
SMs/1000 SMs, while prescription prevalence varied from 16.0
to 17.6 prescriptions/1000 SMs.
3.3. Replacement preparations
For replacement preparations (Fig. 2B), there was an increase
from 2005 to 2011 in both the prevalence of SMs filling
prescriptions and the prevalence of prescriptions filled. This
was followed by a small decline from 2011 to 2013. From 2005
to 2011, the prevalence of SMs filling prescriptions increased
from 15.1 to 22.2 SMs/1000 SMs, and prescriptions from 21.5 to
28.9 prescriptions/1000 SMs.
In the present study, 97% of replacement preparations
involved calcium salts (74%), zinc preparations (12%) and
potassium preparations (11%). When the replacement prepa-
rations were partitioned into these three major mineral
compounds (Fig. 3A), it could be seen that prescriptions for
calcium salts were increasing while those for zinc prepara-
tions declined precipitously beginning in 2007, reaching a very
low level by 2009.
3.4. Antacids and absorbents
The prevalence of SMs filling antacids/absorbent prescrip-
tions (Fig. 2C) declined at a rate of 0.81 SMs/1000 SMs per yeary = -0.2317x + 36.358
R² = 0.725, SEE=0.417, P = .004
y = -0.587x + 54.553
R² = 0.882, SEE=0.630, P < .001
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dels. For details see the statistical analyses section.
y = -0.133x + 12.758
R² = 0.932, SEE=0.105, P < .001
y = -0.1917x + 17.536
R² = 0.746, SEE=0.328, P = .003
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codes during the survey period. Curve-fitting techniques were applied to the graphed data, primarily using linear and
quadratic models. For details see the statistical analyses section.
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of prescriptions for antacids/absorbents declined at a rate of
0.64 prescriptions/1000 SMs per year or 5.76 prescriptions/
1000 SMs over the 9-year period. SM prevalence declined from
8.3 SMs/1000 SMs in 2005 to 3.5 SMs/1000 SMs in 2013;
prescription incidence declined from 10.5 prescriptions/1000
SMs in 2005 to 4.2 prescriptions/1000 SMs in 2013.
3.5. Cathartics and laxatives
Trends in cathartics and laxatives are shown in Fig. 2D and
required complex curve-fitting techniques that did not assist
in interpreting the trends over time. In general, there was a
decline in both SM and prescription prevalence after 2008
which returned to near 2008 levels after 2012. Yearly SM
prevalence varied between 12.0 and 16.8 SMs/1000 SMs while
prescription prevalence varied between 14.5 and 19.8 pre-
scriptions/1000 SMs.
3.6. Vitamins
Fig. 4 shows trends in prescriptions for four vitamins.
The prevalence of SMs receiving B and B-complex vitamins
(Fig. 4A) declined at a rate of 2.86 SMs/1000 SMs/y., or 26.01
SMs/1000 SMs over the 9-year period. The prevalence of
prescriptions declined at a much slower rate, 0.82 prescrip-
tions/SMs/y. or 7.38 prescriptions/1000 SMs over the 9-year
period. These data demonstrated that a smaller number of SMs
were receivingmore B and B-complex vitamin prescriptions asy = -0.816x + 15.544
R² = 0.938, SEE=0.613, P < .001
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R² = 0.892, SEE=2.913, P < .001
0
10
20
30
40
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
SMs Filling Prescriptions
Prescriptions Filled
y = 0.335x2 - 1.099x + 1.076
R² = 0.992, SEE=0.662, P < .001
y = 0.465x2 - 1.433x + 1.477
R² = 0.992, SEE=0.957, P < .001
0
5
10
15
20
25
30
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
SMs Filling Prescriptions
Prescriptions Filled
SM
 F
ill
in
g 
Pr
es
cr
ip
tio
ns
/1
00
0 
SM
s 
or
 P
re
sc
rip
tio
ns
 F
ill
ed
/1
00
0 
SM
s A – Vitamin B and B Complex
C – Vitamin D
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(B), vitamin D (C), and vitamin E (D). Data were graphed by year t
survey period. Curve-fitting techniques were applied to the grap
details see the statistical analyses section.the 9-year period progressed. Vitamin C prescriptions (Fig. 4B)
almost doubled in both SM prevalence and prescription
prevalence from 2005 to 2008–2009 but after 2009 there was
little change in eithermeasure. For VitaminD (Fig. 4C), both SM
and prescription prevalence increased dramatically during the
9-year survey period. For SM prevalence, the change was 55-
fold (0.3 to 18.3 SMs/1000 SMs) and for prescription prevalence,
the change was 42-fold (0.6 to 26.2 prescriptions/1000 SMs).
Finally, Vitamin E SM and prescription prevalence declined
over the survey period from 2005 to 2009 and then changed
little in the following years (Fig. 4D).
Prescriptions filled by SMs for B and B-complex vitamins
primarily consisted of pyridoxine (70%), folate (21%), Vitamin
B12 (5%), and thiamin (2%). When portioned into these
individual substances (Fig. 3B), the decline in B and B-
complex vitamin prescriptions was accounted for almost
exclusively by pyridoxine (Vitamin B6).
3.7. Botanicals
A number of botanical substances (i.e., derived from plants)
were included in the generic classifications. These included 34
generic substances that did not contain any other substances
(single botanicals), and 9 that were botanicals with other
substances. Of the single botanicals, sennosides and psyllium
(both classified as cathartics/laxatives) accounted for 64.4%
and 32.5% of the SMs filling prescriptions, respectively.
Other single botanicals (in order of the proportion of SMs filling
single botanical prescriptions) included baicalin/catechiny = -0.121x2 + 1.562x + 3.661
R² = 0.878, SEE=0.526, P < .001
y = -0.118x2 + 1.614x + 4.561
R² = 0.885, SEE=0.584, P < .001
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or vitamins including vitamin B and B-complex (A), vitamin C
o examine trends in prescriptions by AHFS codes during the
hed data, primarily using linear and quadratic models. For
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(0.34%), garlic (0.24%), and green tea leaf extract (0.23%).
Psyllium with sugars or amino acids accounted for 99.9%
of the SMs filling prescriptions for botanicals that included
other substances.4. Discussion
This is the first investigation to describe the prevalence and
temporal trends in all oral DS prescriptions filled by SMs and
was based directly on pharmacy records classified using the
AHFS. During the study's 9-year surveillance period about 11%
of SMs filled at least one prescription for a DS each year, about
235 180 ± 4926 (mean ± SD) prescriptions per year. We
hypothesized that the overall prevalence of prescriptions
would remain relatively stable over time but there would be
temporal variations in specific categories of DSs. There was a
very small increase in the overall prevalence of SMs filling
prescriptions for oral DSs from 2005 through 2013 so we had
to reject the first part of the hypothesis. However, DSs were
subcategorized into AHFS pharmacologic-therapeutic catego-
ries, significant trends for some classes of DSs were apparent
so the second part of our hypothesis was accepted. There
were increases over time in prescriptions for Vitamin D,
Vitamin C, and replacement compounds; decreases over time
in prescriptions for antacids, B and B-complex Vitamins, and
Vitamin E; and although there was a significant decline in
prescriptions for multivitamins and iron preparations, the
absolute changes over time were relatively small. These
temporal trends may be associated with the changing
perceptions of prescribers of the therapeutic value of these
substances in medicine and public health. In addition,
some patients may have requested specific DSs from their
providers and the nature of these requests may have changed
over time based on patient perceptions of the health or
other benefits of these supplements. Similar changes may
have occurred among civilian healthcare providers and
should be investigated.
The most dramatic trend observed was a large increase in
Vitamin D prescriptions over the survey period. A similar
temporal trend was noted over a shorter, less recent
timeframe (2007–2011) in other data obtained from the PDTS
[24]. In 1997, an Institute of Medicine (IOM) report set the
adequate intake (AI) level of Vitamin D at 200 International
Units (IU) or 5 μg/d for adults 19 to 70 years of age. This level
was based on the amount of intake necessary to achieve a
serum level of plasma 25-hydroxyvitamin D (25(OH)D) (the
accepted clinical indicator of Vitamin D status, including
contributions from both cutaneous and dietary sources) of
about 30 nmol/L (12 ng/L). Subsequently, substantial addi-
tional research indicated that either the plasma 25 (OH) D
levels or the dietary intake of Vitamin D of Americans was
insufficient [28-30]. This was followed by considerable media
attention both in the popular press [31-33] and in scientific/
medical journals [34-36]. More accurate methods of measur-
ing 25(OH)D also became available, although each method
had limitations [37]. In 2009, an IOMworking group concluded
there was significant new and relevant research available to
warrant a reevaluation of the dietary recommendations forVitamin D and calcium [38]. In 2011, the IOM published a new
monograph on Vitamin D [39] based on a comprehensive
analysis of the new information. It suggested that 25(OH)D
levels <30 nmol/L were associated with reduced calcium
absorption and osteomalacia in young and middle aged
adults but there was little evidence of benefits for levels >50
nmol/L. Based on achieving a plasma level of 50 nmol/L, the
committee updated the recommended daily allowance (RDA)
of Vitamin D for those 1 to 70 years of age to 600 IU/d (15 μg/d)
tripling the allowance [39]. The increasing attention devoted
to Vitamin D in the popular and medical literature, better
availability and more accurate assay procedures, knowledge
that large portions of individuals may be Vitamin D deficient,
and the change in national policy may account for the
increase in Vitamin D prescriptions during the survey period.
In contrast to Vitamin D, the data indicated that prescrip-
tions for Vitamin E declined from 2005 to 2009 in agreement
with another study using PDTS data [24]. The actual prescrip-
tion prevalence was relatively low, with a high of about 1.4
prescriptions/1000 SMs in 2005 and declining and stabilizing
at about 0.3 to 0.4 prescriptions/1000 SMs after 2009. During
the survey period, several meta-analytic studies appeared
suggesting that high-dosage Vitamin E supplementation may
increase all-cause mortality [40-42], although the applicability
of these meta-analyses to healthy individuals was questioned
[43]. The recommendation for Vitamin E intake was 15 mg/
day for adults 19 to 50 years of age [44] but data from the
NHANES 2003–2006 indicated that Americans consumed
about 7 mg/day [45]. Nonetheless, signs of overt Vitamin E
deficiency were rare and usually associated with malnutri-
tion, rare genetic conditions, and certain chronic diseases
[46-50]. While observational epidemiological studies sug-
gested that Vitamin E may reduce cardiovascular events,
large randomized prospective cohort trials have generally not
demonstrated favorable effects on cardiovascular disease
[51-53]. Methodological problems with observational epide-
miological studies have been comprehensively outlined
[51,54]. The US Preventive Services Task Force (USPSTF)
recommended against the use of Vitamin E for the primary
prevention of cancer or cardiovascular disease [55,56].
Overall, the meta-analytic studies suggesting high-dose
Vitamin E increases mortality, results of large randomized
prospective cohort trials suggesting little effect on cardiovas-
cular disease and cancer, and recommendations of the
USPSTF may at least in part account for and justify the
decline in Vitamin E prescriptions.
Another interesting trend was the linear decline in
prescriptions for antacids and absorbents. The shape of the
curve suggested that the decline in the survey periodmay be a
continuation of declines from previous years, although
without prior year data this cannot be determined with
certainty. Based on the procedures used by NHANES [57] we
included antacids in our study since they provide users with
specific minerals. Antacids included substances such as
calcium carbonate, magnesium carbonate, magnesium hy-
droxide, sodium bicarbonate, aluminum hydroxide and other
substances mixed with these compounds (e.g., calcium
carbonate with glycine). Antacids are typically prescribed for
rapid relief of mild, infrequent gastroesophageal reflux
disease (GERD) whereby antacids act as buffering agents to
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acid suppressive drugs, histamine 2 receptor antagonists
(H2RAs), was developed. In the 1990’s, proton pump inhibitors
(PPIs) were developed that were extremely effective in
blocking the final common pathway of gastric acid secretion,
the hydrogen/potassium-APTase proton pump [60]. Other
drugs in development or on the market for GERD include
potassium-competitive acid blockers and drugs that reduce
transient lower esophageal sphincter relaxation (TLESR re-
ducers) [61]. A study of a nationally representative sample of
emergency rooms found that while the prescriptions for PPIs
more than doubled from 2001 to 2010, prescriptions for H2RAs
and antacids decreased 16% and 25%, respectively [62]. The
reduction in prescribed antacids seen in the present study
was much greater over a similar period of time (9 years), but
the present data includes all oral prescriptions rather than
just those provided in emergency rooms. It is possible that the
development and use of advanced drugs for treating GERD
resulted in a decline in prescriptions for antacids during the
survey period.
Replacement preparations are a very broad category of
substances designed to treat a variety of specific nutritional
deficiencies. Prescriptions for replacement preparations in-
creased from 2005 to 2011 then declined very slightly. When
partitioned into the mineral compounds accounting for most
of these (calcium salts and zinc preparations), it could be seen
that prescriptions for calcium salts were increasing while
those for zinc preparations declined precipitously. Despite
differences in methodology noted earlier (i.e., subject popula-
tion and timeframe), Attipoe et al [23] noted similar trends in
calcium and zinc prescriptions. In the present investigation,
there were 22 generic calcium compounds classified as
replacement preparations and 14 (64%) of these contained
some form of Vitamin D. The reasons cited above for the
increases in Vitamin D prescriptions may also, at least partly,
account for the increase in calcium salt preparations over the
survey period. Zinc preparations were primarily zinc acetate,
zinc gluconate, or zinc sulfate in the form of tablets, capsules,
or lozenges. Summaries of studies prior to 1998 suggested
that zinc preparations may reduce the duration and symp-
toms of the common cold [63] but after this time studies were
published indicating that this intervention may not be
effective [64,65], and a structured review of randomized
placebo controlled studies in 2007 suggested there was no
therapeutic benefit from zinc lozenge consumption [66].
Problems with the taste of placebos [67] and the chemistry
of formulations [68] emerged, adding to the uncertainty. The
latest Cochrane review of 18 trials indicated that oral zinc
administered within 24 hours of symptom onset may slightly
shorten the duration of the common cold in healthy people.
There was no association between oral zinc supplements and
symptom severity, and the prevalence of adverse effects with
zinc lozenges was high [69]. Other applications for oral zinc
preparations for infectious, chronic, and age-related diseases
have also been suggested [70,71]. Nonetheless, the uncertain
effectiveness of zinc substances for treating the common cold
may explain, at least in part, the decline in prescriptions for
zinc preparations.
Prescriptions filled by SMs for B and B-complex vitamins
declined during the survey period, accounted for almostexclusively by a decline in pyridoxine (Vitamin B6). Reasons
for this are not clear. Pyridoxine comprised a single generic
category, “pyridoxine HCL”. Pyridoxine is present in a wide
variety of foods so actual deficiency is rare [72]. The RDA for
adults is 1.3 mg/day[72] and, based on data from NHANES,
average intake from food is 1.9 mg/day with 75% of Americans
consuming at least 1.4 mg/day [45]. Clinical uses of pyridoxine
include treatment for certain types of anemia, morning
sickness, premenstrual syndromes, impaired renal function,
and hyperhomocystemia [73-78]. Early observational epide-
miological studies suggested that higher levels of pyridoxine
or its bioactive metabolite (pyridoxal 5′-phosphate) reduced
the risk of cardiovascular disease [79,80], possibly through an
effect on homocysteine that has a dose–response relationship
with cardiovascular disease [81]. However, subsequent ran-
domized prospective placebo controlled trials showed that
supplemental pyridoxine did not affect homocysteine levels
or the incidence of cardiovascular events [82,83]. Pyridoxine
has also been suggested for the treatment of peripheral
neuropathies including carpal tunnel syndrome [84,85] but
randomized double-blinded placebo controlled studies or a
meta-analysis found no evidence of advantageous therapeutic
effects [86-88]. Although it is difficult tomake direct comparisons
for reasons noted above (participant population and timeframe),
aswell as the fact that only the total number of prescriptionswas
examined, Krieger et al. [22] noted a decline in overall prescrip-
tions Vitamin B and in pyridoxine prescriptions in military
medical treatment facilities from 2007 to 2011.
Vitamin C prescription prevalence rose from 2005 to 2009,
almost doubling in this period, and then leveled off over the
remainder of the surveillance period. Morioka et al. [24] using
PDTS data reported a small increase in Vitamin C prescrip-
tions in the period 2007–2011 which is relatively consistent
with the data reported here. Of the 3 generic categories for
Vitamin C, over 99% of the prescriptions were for “ascorbic
acid” with very few prescriptions for the other two generic
categories (ascorbic acid with ascorbate sodium and ascorbic
acid with Vitamin E). Since 1970, when Linus Pauling
published a book claiming that Vitamin C prevents and
ameliorates the common cold, this has been a controversial
topic [89]. In 2004, a systematic review was published
indicating that dosages of 200 mg/day or greater did not
appear to reduce the incidence of colds in the general
population; however, studies involving military personnel
and participants living under conditions similar to those of
military recruits (i.e., close living quarters and heavy physical
exercise) generally indicated that Vitamin C reduced the
incidence of common colds and pneumonia [90]. Subsequent-
ly, other systematic and narrative reviews published between
2005 and 2013 came to similar conclusions [91-95]. With
regard to the treatment or prevention of cancer or cardiovas-
cular disease, systematic and narrative reviews of random-
ized clinical trials have generally concluded that Vitamin C is
not effective [56,96-98]. One problem with intervention
studies is that Vitamin C is tightly regulated in humans by
mechanisms involving absorption, tissue accumulation, and
renal reabsorption and excretion. In studies where subjects'
baseline Vitamin C levels were already saturated, supple-
mentation may have no effect [99]. A recent randomized
double-blinded placebo controlled trial of healthy men with
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below adequate, <28 μmol/L) found that 1gm/day of oral
Vitamin C reduced the incidence and duration of colds
compared to a placebo [100]. It is possible that favorable
reviews regarding Vitamin C and the common cold in
military personnel influenced the trend in Vitamin C
prescriptions.
Sennosides and psyllium were the most commonly
prescribed substances derived from botanical constituents.
These two substances have well known and well established
therapeutic uses as laxatives [101-103] and were classified as
such in the AHFS codes. In addition, psyllium has been used
for the treatment of hypercholesterolemia, diabetes, irritable
bowel syndrome, ulcerative colitis, and other maladies
[103-105]. The third most common botanical was baicalin/
catechin (primarily Limbrel®), which is a flavonoid deriva-
tive and a cyclooxygenase inhibitor (COX 1 and COX 2) used
in the treatment of osteoarthritis [106,107]. Other botanicals
such as Ginkgo biloba, flaxseed, garlic, green tea leaf extract
and ginseng may have some therapeutic applications, but
have also been associated with adverse effects [108-110]. It is
not clear why they had been prescribed by medical care
providers.
The present study found that about 11% of SMs filled at
least one prescription for a DS each year. We previously found
that 60% to 70% of SMs self-reported using at least one DS [4].
Thus, it seems likely that most SMs obtain their DSs from
over-the-counter sources.
The strength of this study is that the data on prescribed
DSs are likely to be complete. Prescription medication is free
for SMs and SMs are likely to use themilitary medical system
for this reason. Further, the data includes the actual DS
dispensed from the pharmacies and not just those pre-
scribed. However, there is no guarantee that the SM will use
the DS once obtained. Two individuals independently
selected the DSs and there were few disagreements with
these resolved by consensus. Future studies may attempt to
combine medical records data with pharmacy data to see if
prescriptions are appropriate to the problem.
In summary, the present study describes trends in
prescribed oral DSs dispensed to military personnel from
2005 through 2013. We found that 11% of SMs filled one or
more oral DS prescriptions in this period. There were
increases over time in prescriptions for Vitamin D, Vitamin
C, and replacement compounds; decreases over time in
prescriptions for antacids, Vitamin B and B-complex, and
Vitamin E; and little change for iron preparations and
multivitamins. Accounting for these trends is likely com-
plex, and an attempt was made here to explain the
observed patterns in terms of changes in the roles of DSs
in therapeutics and public health. Both provider and
patient perceptions and knowledge are likely important
in interpreting the trends. If a patient is seeing a provider,
it is relatively easy to request a DS the patient may
consider important for health but not associated with the
specific problem of the visit. Knowledge and perceptions of
the uses of DSs will continue to evolve and continuing
surveillance of these DSs will identify if the trends
observed here continue into the future or if new patterns
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